title: Cholecystokinin-58 and cholecystokinin-8 produce similar but not identical activations of myenteric plexus and dorsal vagal complex.
abstract: The enteric nervous system (ENS: myenteric and submucosal plexuses) of the gastrointestinal tract may have a role in the reduction of food intake by cholecystokinin (CCK). Exogenous cholecystokinin-8 (CCK-8) activates the myenteric plexus and the feeding control areas of the dorsal vagal complex (DVC) of the brainstem. An increasing number of reports, however, have shown that CCK-58 is the sole or the major circulating form of CCK in rat, human and dog, and that it is qualitatively different from CCK-8 in evoking various gastrointestinal physiological responses (e.g., contraction of the gallbladder and exocrine pancreatic secretion). In the current report, we compared the abilities of exogenous CCK-58 to activate the myenteric plexus and the dorsal vagal complex with those of exogenous CCK-8 by quantifying Fos-like immunoreactivity (Fos-LI; a marker for neuronal activation). We report that CCK-58 (1, 3, and 5 nmol/kg) increased Fos-LI in the myenteric plexus (p<0.001) and in the DVC (p<0.001) compared to the saline vehicle. The highest dose of CCK-58 increased Fos-LI more than an equimolar dose of CCK-8 in the myenteric plexus and the area postrema. Thus, CCK-8 and CCK-58 produce the same qualitative pattern of activation of central and peripheral neurons, but do not provoke identical quantitative patterns at higher doses. The different patterns produced by the two peptides at higher doses, in areas open to the circulation (myenteric plexus and area postrema) may reflect endocrine actions not observed at lower doses.
authors.affiliation: Gastroenterology Laboratory, Department of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, Alabama, USA.
authors.forename: Marvis S
authors.initials: MS
authors.lastname: Cooper
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Reeve
authors.forename: Shannon J
authors.initials: SJ
authors.lastname: Raboin
authors.forename: Mohamed O
authors.initials: MO
authors.lastname: Abdalla
authors.forename: Gary M
authors.initials: GM
authors.lastname: Green
authors.forename: Ayman I
authors.initials: AI
authors.lastname: Sayegh
mesh_terms: D000818:Animals; D002766:Cholecystokinin / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects; D007150:Immunohistochemistry; D009197:Myenteric Plexus / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014630:Vagus Nerve / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000099169:Fos-Related Antigen 1
chemical_list: D002766:Cholecystokinin; D010446:Peptide Fragments; D016760:Proto-Oncogene Proteins c-fos; D000099169:Fos-Related Antigen 1; C410885:cholecystokinin 8; C038823:cholecystokinin 58